Goldberg Andrew D. 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 11, 2025
Insider Transaction Report
Form 4
Goldberg Andrew D.
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-03-07−7,000→ 0 totalExercise: $12.89Exp: 2032-06-15→ Common Stock (7,000 underlying) - Exercise/Conversion
Common Stock
2025-03-07$12.89/sh+7,000$90,230→ 13,350 total
Footnotes (1)
- [F1]Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option vested in full on the one-year anniversary of the date of grant.